nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

23.04.2016 | Editorial Commentary

Dual-phase amyloid PET: hitting two birds with one stone

verfasst von: Garibotto Valentina, Morbelli Silvia, Pagani Marco

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Excerpt

One of the major breakthroughs in Alzheimer’s disease (AD) clinical research over the past two decades has been the validation of diagnostic biomarkers able to demonstrate the presence of pathological mechanisms of AD and to predict further cognitive decline and dementia onset in mild cognitive impairment (MCI) patients by identifying the prodromal stage of AD [1, 2]. Among AD biomarkers, two main categories exist: (1) amyloidosis biomarkers, able to identify a molecular feature typical of AD: these include cerebrospinal fluid (CSF) amyloid-β42 reduction and PET imaging using radiotracers selectively binding to the fibrillar aggregates of amyloid-β plaques; (2) neurodegeneration biomarkers reflecting neuronal injury, such as the increase of tau and phosphorylated-tau levels in the CSF, regional atrophy as measured by MRI and demonstration of synaptic dysfunction/degeneration by means of 18F-fluorodeoxyglucose (FDG) PET. Neurodegeneration biomarkers are useful tools for further differential diagnosis among amyloid positive and amyloid negative forms of dementia, and also a prognostic tool in the MCI population. …

Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734–46. doi:10.1016/S1474-4422(07)70178-3.CrossRefPubMed

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–9. doi:10.1016/j.jalz.2011.03.008.CrossRefPubMedPubMedCentral

Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010;9(11):1118–27. doi:10.1016/S1474-4422(10)70223-4.CrossRefPubMed

Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–29. doi:10.1016/S1474-4422(14)70090-0.CrossRefPubMed

Vos SJ, Verhey F, Frolich L, Kornhuber J, Wiltfang J, Maier W, et al. Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage. Brain. 2015;138(Pt 5):1327–38. doi:10.1093/brain/awv029.CrossRefPubMed

Bocchetta M, Galluzzi S, Kehoe PG, Aguera E, Bernabei R, Bullock R, et al. The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey. Alzheimers Dement. 2015;11(2):195–206 e1. doi:10.1016/j.jalz.2014.06.006.CrossRefPubMed

Teipel S, Drzezga A, Grothe MJ, Barthel H, Chetelat G, Schuff N, et al. Multimodal imaging in Alzheimer’s disease: validity and usefulness for early detection. Lancet Neurol. 2015;14(10):1037–53. doi:10.1016/S1474-4422(15)00093-9.CrossRefPubMed

Carrillo MC, Blennow K, Soares H, Lewczuk P, Mattsson N, Oberoi P, et al. Global standardization measurement of cerebral spinal fluid for Alzheimer’s disease: an update from the Alzheimer’s Association Global Biomarkers Consortium. Alzheimers Dement. 2013;9(2):137–40. doi:10.1016/j.jalz.2012.11.003.CrossRefPubMed

Lin KJ, Hsiao IT, Hsu JL, Huang CC, Huang KL, Hsieh CJ, et al. Imaging characteristic of dual-phase F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer’s disease and mild cognitive impairment. Eur J Nucl Med Mol Imaging. 2016. doi:10.1007/s00259-016-3359-8.

10.

Hsiao IT, Huang CC, Hsieh CJ, Hsu WC, Wey SP, Yen TC, et al. Correlation of early phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging. 2012;39(4):613–20. doi:10.1007/s00259-011-2051-2.CrossRefPubMed

11.

Blomquist G, Engler H, Nordberg A, Ringheim A, Wall A, Forsberg A, et al. Unidirectional influx and net accumulation of PIB. Open Neuroimag J. 2008;2:114–25. doi:10.2174/1874440000802010114.CrossRefPubMedPubMedCentral

12.

Rodriguez-Vieitez E, Carter SF, Chiotis K, Saint-Aubert L, Leuzy A, Scholl M, et al. Comparison of early phase 11C-deuterium-l-deprenyl and 11C-PiB PET for assessing brain perfusion in Alzheimer’s disease. J Nucl Med. 2016. doi:10.2967/jnumed.115.168732.

13.

Forsberg A, Engler H, Blomquist G, Langstrom B, Nordberg A. The use of PIB-PET as a dual pathological and functional biomarker in AD. Biochim Biophys Acta. 2012;1822(3):380–5. doi:10.1016/j.bbadis.2011.11.006.CrossRefPubMed

14.

Rostomian AH, Madison C, Rabinovici GD, Jagust WJ. Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med. 2011;52(2):173–9. doi:10.2967/jnumed.110.082057.PubMedPubMedCentral

15.

Gietl AF, Warnock G, Riese F, Kalin AM, Saake A, Gruber E, et al. Regional cerebral blood flow estimated by early PiB uptake is reduced in mild cognitive impairment and associated with age in an amyloid-dependent manner. Neurobiol Aging. 2015;36(4):1619–28. doi:10.1016/j.neurobiolaging.2014.12.036.CrossRefPubMed

16.

Farid K, Hong YT, Aigbirhio FI, Fryer TD, Menon DK, Warburton EA, et al. Early phase 11C-PiB PET in amyloid angiopathy-related symptomatic cerebral hemorrhage: potential diagnostic value? PLoS One. 2015;10(10), e0139926. doi:10.1371/journal.pone.0139926.CrossRefPubMedPubMedCentral

17.

Wimo A, Ballard C, Brayne C, Gauthier S, Handels R, Jones RW, et al. Health economic evaluation of treatments for Alzheimer’s disease: impact of new diagnostic criteria. J Intern Med. 2014;275(3):304–16. doi:10.1111/joim.12167.CrossRefPubMed

18.

Valcarcel-Nazco C, Perestelo-Perez L, Molinuevo JL, Mar J, Castilla I, Serrano-Aguilar P. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer’s disease. J Alzheimers Dis. 2014;42(3):777–88. doi:10.3233/JAD-132216.PubMed

19.

Moulin-Romsee G, Maes A, Silverman D, Mortelmans L, Van Laere K. Cost-effectiveness of 18F-fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective. Eur J Neurol. 2005;12(4):254–63. doi:10.1111/j.1468-1331.2004.00940.x.CrossRefPubMed

20.

Hornberger J, Michalopoulos S, Dai M, Andrade P, Dilla T, Happich M. Cost-effectiveness of florbetapir-PET in Alzheimer’s disease: a Spanish societal perspective. J Ment Health Policy Econ. 2015;18(2):63–73.PubMed

21.

Lim HK, Nebes R, Snitz B, Cohen A, Mathis C, Price J, et al. Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects. Brain. 2014;137(Pt 12):3327–38. doi:10.1093/brain/awu271.CrossRefPubMedPubMedCentral

22.

Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2013;40(1):104–14. doi:10.1007/s00259-012-2237-2.CrossRefPubMedPubMedCentral

23.

Prestia A, Caroli A, Wade SK, van der Flier WM, Ossenkoppele R, Van Berckel B, et al. Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimers Dement. 2015;11(10):1191–201. doi:10.1016/j.jalz.2014.12.001.CrossRefPubMed

24.

Zhang S, Han D, Tan X, Feng J, Guo Y, Ding Y. Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer’s disease in subjects with mild cognitive impairment. Int J Clin Pract. 2012;66(2):185–98. doi:10.1111/j.1742-1241.2011.02845.x.CrossRefPubMed

25.

Garibotto V, Herholz K, Boccardi M, Picco A, Varrone A, Nordberg A et al. Maturity of FDG-PET as a biomarker for Alzheimer’s disease in the context of a structured 5–phase development framework. Neurobiol Aging (in press).

26.

Pagani M, De Carli F, Morbelli S, Oberg J, Chincarini A, Frisoni GB, et al. Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer’s disease from healthy controls. A European Alzheimer’s Disease Consortium (EADC) study. Neuroimage Clin. 2015;7:34–42. doi:10.1016/j.nicl.2014.11.007.CrossRefPubMedPubMedCentral

27.

Morbelli S, Garibotto V, Van De Giessen E, Arbizu J, Chetelat G, Drezgza A, et al. A Cochrane review on brain [(1)(8)F]FDG PET in dementia: limitations and future perspectives. Eur J Nucl Med Mol Imaging. 2015;42(10):1487–91. doi:10.1007/s00259-015-3098-2.CrossRefPubMed

28.

Cerami C, Della Rosa PA, Magnani G, Santangelo R, Marcone A, Cappa SF, et al. Brain metabolic maps in mild cognitive impairment predict heterogeneity of progression to dementia. Neuroimage Clin. 2015;7:187–94. doi:10.1016/j.nicl.2014.12.004.CrossRefPubMedPubMedCentral

29.

Villain N, Desgranges B, Viader F, de la Sayette V, Mezenge F, Landeau B, et al. Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer’s disease. J Neurosci. 2008;28(24):6174–81. doi:10.1523/JNEUROSCI.1392-08.2008.CrossRefPubMedPubMedCentral

30.

Silverman DH. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med. 2004;45(4):594–607.PubMed

31.

Verclytte S, Lopes R, Lenfant P, Rollin A, Semah F, Leclerc X, et al. Cerebral hypoperfusion and hypometabolism detected by arterial spin labeling MRI and FDG-PET in early onset Alzheimer’s disease. J Neuroimaging. 2016;26(2):207–12. doi:10.1111/jon.12264.CrossRefPubMed

Titel: Dual-phase amyloid PET: hitting two birds with one stone
verfasst von: Garibotto Valentina
Morbelli Silvia
Pagani Marco
Publikationsdatum: 23.04.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3393-6

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2016

Nami Azar and Carolyn K. Donaldson (Eds): RadCases. Ultrasound Imaging. Thieme Publishers New York 2015, ISBN: 978-1-60406322-6

Imaging of brain TSPO expression in a mouse model of amyotrophic lateral sclerosis with 18F-DPA-714 and micro-PET/CT

Imaging characteristic of dual-phase 18F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer’s disease and mild cognitive impairment

Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT

Reduction in camera-specific variability in [123I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls

Erratum to: EANM '15 Annual Congress of the European Association of Nuclear Medicine, October 10–14, 2015, Hamburg, Germany